Vimarsana
Biggest News Aggregation in the World

Lon Fab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lon Fab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lon Fab Today - Breaking & Trending Today

Fusion Antibodies (LON:FAB) Stock Price Down 16% - Vimarsana News

Fusion Antibodies (LON:FAB) Stock Price Down 16%

Fusion Antibodies plc (LON:FAB – Get Rating)’s share price dropped 16% during trading on Thursday . The company traded as low as GBX 28.50 ($0.36) and last traded at GBX 31.50 ($0.39). Approximately 150,049 shares changed hands during mid-day trading, an increase of 547% from the average daily volume of 23,194 shares. The stock had […]

Fusion Antibodies (LON:FAB) Stock Price Down 4.2% - Vimarsana News

Fusion Antibodies (LON:FAB) Stock Price Down 4.2%

Fusion Antibodies plc (LON:FAB – Get Rating)’s stock price traded down 4.2% during trading on Wednesday . The company traded as low as GBX 33.05 ($0.41) and last traded at GBX 34 ($0.42). 1,032 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 22,797 shares. The stock had […]

Fusion Antibodies (LON:FAB) Stock Price Down 11.7% - Vimarsana News

Fusion Antibodies (LON:FAB) Stock Price Down 11.7%

Fusion Antibodies plc (LON:FAB – Get Rating) fell 11.7% on Monday . The company traded as low as GBX 34 ($0.42) and last traded at GBX 34 ($0.42). 22 shares changed hands during trading, a decline of 100% from the average session volume of 24,802 shares. The stock had previously closed at GBX 38.50 ($0.48). […]

Director Deals - (FAB) | 17 December 2021 | Stock Market Wire - Vimarsana News

Director Deals - (FAB) | 17 December 2021 | Stock Market Wire

Director Deals - (FAB)

Fusion Antibodies sees revenue growth 'marginally ahead' of market expectations | 4 May 2021 - Vimarsana News

Fusion Antibodies sees revenue growth 'marginally ahead' of market expectations | 4 May 2021

Fusion Antibodies sees revenue growth 'marginally ahead' of market expectations